The Institute for Clinical and Economic Review voted 11-2 that Merck’s molnupiravir doesn’t work as well against coronavirus infections as Paxlovid or fluvoxamine, but the drug price watchdog says all three treatments are reasonably priced for their efficacy levels. ICER released its final evidence report on the three COVID-19 treatments Tuesday (May 10). The final report excludes sotrovimab, which had been included in the earlier draft report. ICER also recommends payers and drug makers consider subscription-based or volume-based purchasing models...